T. Rowe Price Associates
KYTX icon

T. Rowe Price Associates’s Kyverna Therapeutics KYTX Stock Holding History

T. Rowe Price Associates’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Sell
1,186,023
-369,264
-24% -$3.28M ﹤0.01% 1314
2026
Q1 		$13.4M Sell
1,555,287
-207,330
-12% -$1.73M ﹤0.01% 1144
2025
Q4 		$16.6M Buy
1,762,617
+250,418
+17% +$1.86M ﹤0.01% 1104
2025
Q3 		$9.07M Sell
1,512,199
-318,302
-17% -$1.27M ﹤0.01% 1251
2025
Q2 		$5.62M Buy
1,830,501
+1,250,897
+216% +$3.09M ﹤0.01% 1244
2025
Q1 		$1.12M Sell
579,604
-14,084
-2% -$41.6K ﹤0.01% 1897
2024
Q4 		$2.22M Sell
593,688
-34,534
-5% -$165K ﹤0.01% 1598
2024
Q3 		$3.07M Sell
628,222
-41,335
-6% -$319K ﹤0.01% 1446
2024
Q2 		$5.02M Sell
669,557
-260,077
-28% -$3.97M ﹤0.01% 1224
2024
Q1 		$23.1M Buy
+929,634
New +$25.9M ﹤0.01% 947

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's KYTX Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Kyverna Therapeutics (KYTX) stake by 24% in Q2 2026, selling an estimated $3.28M and leaving 1,186,023 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

T. Rowe Price Associates first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $23.1M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • T. Rowe Price Associates held 1,186,023 shares of Kyverna Therapeutics worth $10.6M as of Q2 2026.
  • T. Rowe Price Associates sold 369,264 Kyverna Therapeutics shares in Q2 2026, an estimated $3.28M.
  • Kyverna Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1314 holding.
  • T. Rowe Price Associates first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • T. Rowe Price Associates's Kyverna Therapeutics position peaked at $23.1M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.